Investors may be tracking sell-side analyst opinions on shares of TG Therapeutics, Inc. (NASDAQ:TGTX). According to analysts polled by Zacks Research, the current consensus target price is $28.8. Analysts and financial institutions may use different methods to value a particular stock. Because of the use of alternate methods, individual price targets may be widely varied. Viewing the consensus target price can help provide a general sense of where the sell-side sees the stock heading in the future. Investors can take a look at the target projections and decide for themselves if they agree with the Street. Investors tend to take a closer look at shares when analysts provide update to price targets.
Dedicated investors are usually on the lookout for promising stocks that have been overlooked by the investment community. They may be searching for companies that have slipped under the radar and are primed for a move higher. Some investors may do the research and locate these stocks that are infrequently in the financial news headlines and are relatively unknown by the average investor. These stocks may be smaller cap, trading on a foreign exchange, or stocks that used to be prominent that have not been part of the conversation recently. Finding these stocks may take some extra research and effort. Investors who are able to do enough digging may be able to find some great names to help support the stock portfolio.
Street analysts often provide stock recommendations for companies that they track. According to analysts polled by Zacks Research, the current average rating on shares of TG Therapeutics, Inc. (NASDAQ:TGTX) is 1. This average rating includes analysts who have given Buy, Sell and Hold ratings on the name. This rating uses a numerical scale from 1 to 5. A 1 would indicate a Buy recommendation, and a score of 5 would point to a Sell recommendation. Out of all the analysts offering recommendations, 5 have rated the stock a Strong Buy or Buy.
Covering analysts are looking for TG Therapeutics, Inc. (NASDAQ:TGTX) to report a current quarter EPS of -0.47 when the company issues their next earnings report. This is the consensus estimate using analysts taken into consideration by Zacks Research. This estimate includes 4 sell-side analysts. For the previous reporting period, the company posted a quarterly EPS of -0.48. Investors will be closely tracking how close the actual comes to the consensus estimate after the next report. Analysts covering the stock are usually very busy during earnings periods. Before the release, they might be revising estimates. After the earnings release, they will closely review the information and update accordingly.
Looking at some recent stock price activity for TG Therapeutics, Inc. (NASDAQ:TGTX), we have spotted shares trading near the $7.4 level. Looking at some popular historical levels, we note that the 52-week high is presently $14.45, and the 52-week low is currently $4.2. When the stock is trading close to the 52-week high or 52-week low, investors may pay extra attention to see if there will be a move through that level. Looking back over the last 12 weeks, the stock has moved -38.84%. Heading back to the start of the year, we can see that shares have moved 59.14%. Over the past 4 weeks, shares have seen a change of -6.92%. Over the last 5 trading sessions, the stock has moved -14.45%.